Loading...
XSHE
002262
Market cap3.53bUSD
Dec 05, Last price  
24.59CNY
1D
0.57%
1Q
-4.36%
Jan 2017
88.25%
IPO
1,084.99%
Name

Jiangsu Nhwa Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002262 chart
P/E
21.84
P/S
4.38
EPS
1.13
Div Yield, %
1.30%
Shrs. gr., 5y
Rev. gr., 5y
6.55%
Revenues
5.70b
+14.56%
638,844,502695,840,266804,825,180952,499,5601,110,938,9541,300,610,8171,587,499,7321,982,496,3932,236,077,0142,501,358,7492,766,567,6223,017,785,7603,393,676,9553,858,168,5904,149,312,4263,361,303,4723,935,664,2194,298,513,0624,973,504,0415,697,633,044
Net income
1.14b
+10.28%
16,823,10016,983,07226,655,71840,699,44454,673,00976,435,323105,647,054139,697,895176,253,603223,271,123258,347,050309,743,047394,634,279524,807,849663,308,783728,821,694797,777,327900,709,3301,036,918,0581,143,564,427
CFO
916m
-12.80%
8,841,01530,989,08248,550,88646,500,88461,271,78761,791,82381,076,208154,164,158194,332,052160,236,857204,235,003277,141,381452,348,798404,524,742305,972,8551,248,348,649701,117,596861,023,1491,050,545,754916,126,503
Dividend
May 15, 20240.32 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.
IPO date
Jul 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT